iQuity, a Nashville-based data science company, is now offering a blood test to aid in the diagnosis of fibromyalgia. The IsolateFibromyalgia test relies on RNA gene expression to identify fibromyalgia, a disorder of unknown origin that causes body-wide pain, fatigue, cognitive issues and other debilitating symptoms.

“RNA analysis is a cutting-edge tool for doctors that has great potential in the field of medical diagnostics,” said Chase Spurlock, iQuity’s CEO, in a press release. “Unlike DNA, which can predict the risk of certain diseases, RNA shows what’s taking place right now in a patient’s cells. That information can speed up the pace of diagnosis for physicians, leading to faster, more effective treatment for patients.”

The IsolateFibromyalgia test is 94 percent accurate, based on iQuity’s clinical validation studies. To develop the test, iQuity compared the long non-coding RNA (lncRNA) of:

  • 106 fibromyalgia patients
  • 353 disease controls, including patients with rheumatoid arthritis, lupus and other rheumatic conditions, plus those with moderate or severe depression
  • 136 healthy controls.

After comparing the three groups, iQuity researchers were able to identify a specific lncRNA pattern among those with fibromyalgia.

Read more of this article from National Pain Report